Peter Sundstrom

Umea, AC, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.

Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.

Journal: Clinical & translational immunology

Published: February 26, 2026

Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome.

Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome.

Journal: Brain : a journal of neurology

Published: February 12, 2026

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Journal: Annals of clinical and translational neurology

Published: December 19, 2025

Human herpesvirus 7 and the risk of developing multiple sclerosis.

Human herpesvirus 7 and the risk of developing multiple sclerosis.

Journal: Brain communications

Published: September 02, 2025

Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.

Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.

Journal: European journal of neurology

Published: July 08, 2025

Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.

Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.

Journal: Neurology

Published: June 10, 2025

Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis.

Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis.

Journal: European journal of neurology

Published: February 23, 2024

Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.

Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.

Journal: Annals of neurology

Published: January 30, 2024

Prevalence and disease disability in immigrants with multiple sclerosis in Malmö, southern Sweden.

Prevalence and disease disability in immigrants with multiple sclerosis in Malmö, southern Sweden.

Journal: Clinical neurology and neurosurgery

Published: December 18, 2023

Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.

Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.

Journal: Brain : a journal of neurology

Published: October 07, 2023

Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.

Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 21, 2023

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.

Journal: Frontiers in immunology

Published: May 09, 2023

Showing 1-12 of 73

Last Updated: 09/26/2026